Printer Friendly

AEQUITRON MEDICAL ANNOUNCES MARKET RELEASE OF NEW GENERATION OXYGEN CONCENTRATOR

 AEQUITRON MEDICAL ANNOUNCES MARKET RELEASE
 OF NEW GENERATION OXYGEN CONCENTRATOR
 MINNEAPOLIS, March 30 /PRNewswire/ -- Aequitron Medical, Inc. (NASDAQ: AQTN) announced today that the U.S. Food and Drug Administration (FDA) has cleared for immediate market release the new Aequitron Silent Partner II oxygen concentrator. The Silent Partner II, a next generation version of the original Silent Partner, separates oxygen from other atmospheric gases, and then delivers the oxygen to a patient via a flow-rate control device.
 Aequitron acquired the Silent Partner technology in June of 1990 and has completely redesigned the product to respond to evolving demands in the home healthcare market, according to Aequitron President and CEO Curtis J. Olson. "We are very excited about the release of the Silent Partner II because it strengthens the company's ability to aggressively compete in the $100 million-plus worldwide oxygen concentrator market. The domestic and international markets for oxygen concentrators are dynamic and we are now in a better position than ever to accommodate the needs of that marketplace," Olson said. The company expects to begin shipments of the Silent Partner II in the latter part of April.
 With other oxygen delivery systems, oxygen tanks need to be frequently replaced or replenished with liquid oxygen. Oxygen concentrators are more cost-effective than liquid oxygen because they do not require costly visits
from a distributor. Additionally, they ensure an ongoing supply of oxygen to the patient.
 This newly engineered version of the Silent Partner delivers to the user a full 5-liter volume of oxygen. The 5-liter volume has become the industry standard.
 "The technology and price of the Silent Partner II make it one of the most competitive oxygen concentrators available," said Olson. Additionally, it is widely recognized as the quietest running concentrator in existence, ensuring the most enhanced lifestyle possible for the patient.
 Aequitron continues to focus on providing quality customer service in the home healthcare market, Olson said. Medical professionals need to know that the medical devices they prescribe for their patients will provide them with a higher quality of life. The Silent Partner II was engineered with those parameters in mind.
 Aequitron Medical, Inc. designs, manufactures and markets electronic products for home healthcare and hospital use; and wheelchair lifts and automobile hand controls for the mobility impaired. The company's common stock is traded on the National Market System under the NASDAQ symbol AQTN.
 -0- 3/30/92
 /CONTACT: Dave Neuger, 612-333-6621 or 612-699-6730 (Home), or Ed Neuger, 612-333-6621 or 612-929-0945 (Home), both of Neuger and Associates for Aequitron Medical/
 (AQTN) CO: Aequitron Medical, Inc. ST: Minnesota IN: MTC SU: PDT


AL -- MN009 -- 2981 03/30/92 15:08 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 30, 1992
Words:438
Previous Article:CLOTHESTIME OPENS FOUR FLORIDA STORES
Next Article:A NEW PUBLIC AFFAIRS JOURNAL WITHOUT A POLITICAL AGENDA
Topics:


Related Articles
INVACARE UNVEILS COMPREHENSIVE NEW MOBILAIRE PRODUCT LINE FOR HOME RESPIRATORY MARKET
AEQUITRON MEDICAL REPORTS FOURTH QUARTER SALES AND EARNINGS
AEQUITRON MEDICAL ANNOUNCES EARNINGS INCREASE IN FIRST QUARTER
AEQUITRON REPORTS RECORD QUARTERLY SALES AND HIGHER OPERATING EARNINGS FOR SECOND QUARTER
AEQUITRON'S CROW RIVER SUBSIDIARY INTRODUCES ULTRAGATER HIGH-PERFORMANCE WHEELCHAIR LIFT
AEQUITRON MEDICAL EXITS UNPROFITABLE OXYGEN CONCENTRATOR PRODUCT LINE; COMPANY EXPECTS TO ANNOUNCE LOSS FOR FIRST QUARTER
AEQUITRON MEDICAL ANNOUNCES FIRST QUARTER RESULTS
AEQUITRON MEDICAL REPORTS BEST YEAR-END RESULTS IN COMPANY'S HISTORY
AEQUITRON MEDICAL RECEIVES FDA MARKETING RELEASE FOR LP20 VOLUME VENTILATOR
CAIRE Introduces New Home Oxygen Concentrators

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters